Your Destination for TCT 2022 Resources
81% Survival at 30 Days in a Multi-Center, Multi-Society Study of Impella®-Supported AMICS Patients in Japan
Sunday Lunch Symposium On-Demand The CAD’s Out of the Bag: Achieving Heart Recovery in High-Risk Revascularization
Part One: Influential Trials in High-Risk PCI: Shaping the Future of Ischemic Heart Failure Therapy
Jonathan Hill, MD
Part Two: Percutaneous Mechanical Support for PCI in Surgically Ineligible Patients: Preliminary Results from the OPTIMUM Study
Adam Salisbury, MD, Mac
Part Three: The Impact of Unloading: What We May Learn from the STEMI DTU RCT
Navin Kapur, MD
Impella heart pumps are not FDA approved for use in STEMI patients without cardiogenic shock.
Part Four: Contemporary Techniques for Optimal Outcomes in High-Risk PCI
Kate Kearney, MD, FSCAI
TCT Recap of Saturday, September 17
Chuck Simonton, MD, and Seth Bilazarian, MD, present highlights from the first day of presentations at TCT 2022.
TCT Recap of Sunday, September 18
Watch Bobbi Bogaev, MD, and Seth Bilazarian, MD, discuss data, late-breaking clinical trials and TCT 2022 news.
TCT Recap of Monday, September 19
Watch Chuck Simonton, MD, and Seth Bilazarian, MD, discuss data, late-breaking clinical trials and TCT 2022 news.
Data Integrity in Real-World Evidence
Robert Yeh, MD, discusses how we analyze data, make treatment decisions and participate in developing clinical evidence.
Impella is Associated with Improvement in LV Function, Reduction of Major Adverse Events, Higher Survival Rates in Cardiogenic Shock and Improved Quality of Life
More Than 235,000 Patients Supported with Impella Heart Pumps
Impella heart pumps allow a heart team to achieve high-risk revascularization and heart recovery in the cath lab and OR. Impella heart pumps provide the unique benefit of unloading the heart while providing coronary perfusion and end organ perfusion.
Sign Up for Latest Updates
IMP-3663